Business
Novartis Pays Up to $900M for a Chinese Biotech’s Radioactive Cancer Drug
The deal for a preclinical radioligand therapy deepens Novartis’s lead in targeted radioactive cancer treatment — and adds to a rush of Western pharma licensing innovative assets from China.